Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.50
Bid: 1,604.00
Ask: 1,604.50
Change: 4.50 (0.28%)
Spread: 0.50 (0.031%)
Open: 1,600.50
High: 1,612.50
Low: 1,591.00
Prev. Close: 1,595.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS: Panmure Upgrades Shire To Buy From Hold

Thu, 16th Oct 2014 08:36

LONDON (Alliance News) - The following UK shares received analyst recommendations Thursday morning:
----------
FTSE 100
----------
BERENBERG CUTS ROLLS-ROYCE PRICE TARGET TO 1160 (1216) PENCE - 'BUY'
----------
UBS RAISES ANTOFAGASTA TO 'NEUTRAL' ('SELL') - TARGET 710 PENCE
----------
UBS CUTS ANGLO AMERICAN PRICE TARGET TO 1450 (1700) PENCE - 'NEUTRAL'
----------
UBS CUTS BHP BILLITON PRICE TARGET TO 2100 (2300) PENCE - 'BUY'
----------
UBS CUTS RIO TINTO PRICE TARGET TO 3500 (3900) PENCE - 'BUY'
----------
GOLDMAN RAISES RIO TINTO PRICE TARGET TO 2600 (2550) PENCE - 'CONVICTION SELL LIST'
----------
UBS CUTS FRESNILLO PRICE TARGET TO 1000 (1050) PENCE - 'BUY'
----------
BARCLAYS RAISES ASTRAZENECA PRICE TARGET TO 4150 (4100) PENCE - 'EQUAL WEIGHT'
----------
TRADERS: MERRILL LYNCH ADDS ASTRAZENECA TO 'EUROPE 1 LIST'
----------
BARCLAYS CUTS GLAXOSMITHKLINE PRICE TARGET TO 1485 (1500) PENCE - 'EQUAL WEIGHT'
----------
BARCLAYS RAISES SHIRE PRICE TARGET TO 4100 (3900) PENCE - 'OVERWEIGHT'
----------
PANMURE RAISES SHIRE TO 'BUY' ('HOLD') - TARGET 4200 (5300) PENCE
----------
GOLDMAN CUTS BABCOCK INTERNATIONAL PRICE TARGET TO 1380 (1405) PENCE - 'BUY'
----------
CREDIT SUISSE CUTS ARM PRICE TARGET TO 1000 (1100) PENCE - 'OUTPERFORM'
----------
HSBC CUTS WPP PRICE TARGET TO 1540 (1600) PENCE - 'OVERWEIGHT'
----------
TRADERS: NUMIS RAISES WHITBREAD TO 'ADD' ('HOLD')
----------
Numis Cuts Diageo Price Target To 1,800p From 1,900p, Reiterates Hold
----------
FTSE 250
----------
UBS RAISES BELLWAY PRICE TARGET TO 1910 (1870) PENCE - 'BUY'
----------
UBS REMOVES FERREXPO FROM 'LEAST PREFERRED LIST' - 'SELL'
----------
UBS CUTS FERREXPO PRICE TARGET TO 80 (100) PENCE - 'SELL'
----------
UBS CUTS HOCHSCHILD MINING PRICE TARGET TO 135 (185) PENCE - 'NEUTRAL'
----------
UBS CUTS KAZAKHMYS PRICE TARGET TO 340 (370) PENCE - 'BUY'
----------
UBS CUTS LONMIN PRICE TARGET TO 190 (250) PENCE - 'NEUTRAL'
----------
UBS CUTS POLYMETAL PRICE TARGET TO 500 (550) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS BARRATT DEVELOPMENTS PRICE TARGET TO 499 (530) PENCE - 'BUY'
----------
GOLDMAN RAISES BERKELEY GROUP PRICE TARGET TO 2871 (2870) PENCE - 'NEUTRAL'
----------
Numis Upgrades Bank Of Georgia To Buy From Hold, Price Target 2,708 pence
----------
MAIN MARKET AND AIM
----------
GOLDMAN CUTS ASOS PRICE TARGET TO 3000 (4300) PENCE - 'BUY'
----------
GOLDMAN CUTS SHANKS GROUP PRICE TARGET TO 109 (128) PENCE - 'BUY'
----------
Liberum Raises Game Digital Price Target To 265p From 350p, Buy
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
26 Jun 2024 22:50

US CDC narrows age recommendation for RSV shots in US

June 26 (Reuters) - The U.S. CDC on Wednesday narrowed its recommendation for use of respiratory syncytial virus vaccines in older adults this year and held off on recommending their use for adults under age 60.

Read more
26 Jun 2024 11:00

US advisers to consider RSV shots as GSK looks to keep market lead

June 26 (Reuters) - A committee of outside experts to the U.S. CDC are set to vote on whether to expand the age group of adults who should receive respiratory syncytial virus (RSV) vaccines this year, as GSK battles rival Pfizer and new entrant Moderna to keep its top position in the market.

Read more
25 Jun 2024 08:25

Merck KGaA shares plunge after cancer drug hopeful fails

FRANKFURT, June 25 (Reuters) - Shares in Germany's Merck KGaA slumped 8.9% at the open on Tuesday after the diversified group late on Monday said a trial testing a head and neck cancer drug, previously seen as promising, would be stopped for lack of efficacy.

Read more
24 Jun 2024 08:55

TOP NEWS: GSK hails Omjjara approval in Japan; Jemperli review in EU

(Alliance News) - GSK PLC on Monday said it has landed an approval in Japan and also highlighted regulatory progress in the EU.

Read more
24 Jun 2024 07:43

LONDON BRIEFING: Prudential announces buyback; Frasers and THG in deal

(Alliance News) - London's FTSE 100 is called to open lower at the start of the week, with share price falls for major US tech shares, Nvidia included, spooking investors on this side of the Atlantic.

Read more
24 Jun 2024 07:21

GSK reports regulatory progress for Omjjara, Jemperli

(Sharecast News) - GSK announced on Monday that it has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for 'Omjjara', or momelotinib, as a treatment for myelofibrosis.

Read more
20 Jun 2024 16:01

Industry groups back drugmakers' appeal in Zantac cancer lawsuits

June 20 (Reuters) - A bid by GSK and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has received the backing of leading U.S. industry groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America.

Read more
11 Jun 2024 14:31

Zantac litigation fears overdone at GSK, says Shore Capital

(Sharecast News) - Volatile moves in GSK's share price are likely to persist in the near term as a result of ongoing Zantac-related litigation, but the long-term investment case is "still appealing", according to Shore Capital, which kept a 'buy' rating on the stock.

Read more
11 Jun 2024 09:32

TOP NEWS: GSK takes first steps to appeal Zantac ruling in Delaware

(Alliance News) - GSK PLC on Tuesday said it has taken the first steps to seek appeal of a ruling by the Delaware Superior Court in regard to its discontinued heartburn drug Zantac.

Read more
11 Jun 2024 09:12

LONDON MARKET OPEN: FTSE 100 up; UK unemployment rises to 4.4%

(Alliance News) - Stock prices in London opened higher on Tuesday, after a difficult day for markets on Monday amid the EU election fallout.

Read more
11 Jun 2024 07:52

LONDON BRIEFING: FTSE 100 called up despite unemployment rise

(Alliance News) - The FTSE 100 in London was called to open higher on Tuesday, after data showed that unemployment in the UK unexpectedly rose.

Read more
11 Jun 2024 07:22

GSK launches appeal to recent Zantac ruling

(Sharecast News) - GSK has started the process of appealing a recent decision by the Delaware Superior Court regarding the ongoing Zantac, or ranitidine, litigation, it announced on Tuesday.

Read more
11 Jun 2024 00:32

GSK asks to appeal Delaware ruling allowing Zantac cases to go forward

June 10 (Reuters) -

Read more
10 Jun 2024 22:49

Latest trial over Zantac cancer claims called off as plaintiff drops case

June 10 (Reuters) - A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court on Monday, the company announced.

Read more
10 Jun 2024 19:00

TOP NEWS: GSK welcomes dismissal of Zantac case in Illinois

(Alliance News) - GSK PLC on Monday welcomed the dismissal of a case in the US concerning the heartburn drug, Zantac, which was due to start on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.